Literature DB >> 21392983

1α,25-Dihydroxyvitamin D3-3β-bromoacetate, a potential cancer therapeutic agent: synthesis and molecular mechanism of action.

Rahul Ray1, James R Lambert.   

Abstract

Synthesis of 1α,25-dihydroxyvitamin D(3)-3β-bromoacetate (1,25(OH)(2)D(3)-3-BE), a potential anti-cancer agent is presented. We also report that mechanism of action of 1,25(OH)(2)D(3)-3-BE may involve reduction of its catabolism, as evidenced by the reduced and delayed expression of 1α,25-dihydroxyvitamin D(3)-24-hydroxylase (CYP24) gene in cellular assays.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21392983      PMCID： PMC3073821          DOI： 10.1016/j.bmcl.2011.02.025

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  25 in total

1.  Anti-growth effect of 1,25-dihydroxyvitamin D3-3-bromoacetate alone or in combination with 5-amino-imidazole-4-carboxamide-1-beta-4-ribofuranoside in pancreatic cancer cells.

Authors:  Kelly S Persons; Vikram J Eddy; Susan Chadid; Rosangela Deoliveira; Asish K Saha; Rahul Ray
Journal:  Anticancer Res       Date:  2010-06       Impact factor: 2.480

2.  A vitamin D receptor-alkylating derivative of 1α,25-dihydroxyvitamin D3 inhibits growth of human kidney cancer cells and suppresses tumor growth.

Authors:  James R Lambert; Vikram J Eddy; Christian D Young; Kelly S Persons; Sibaji Sarkar; Julie A Kelly; Elizabeth Genova; M Scott Lucia; Douglas V Faller; Rahul Ray
Journal:  Cancer Prev Res (Phila)       Date:  2010-12

3.  Synthesis of 25-hydroxy-[6,19,19'-2H3]vitamin D3 and 1 alpha,25-dihydroxy-[6,19,19'-2H3]vitamin D3.

Authors:  R Ray; D Vicchio; A Yergey; M F Holick
Journal:  Steroids       Date:  1992-03       Impact factor: 2.668

Review 4.  Why do we need a three-dimensional architecture of the ligand-binding domain of the nuclear 1alpha,25-dihydroxyvitamin D(3) receptor?

Authors:  S C Mohr; N Swamy; W Xu; R Ray
Journal:  Steroids       Date:  2001 Mar-May       Impact factor: 2.668

5.  Affinity labeling of the 1 alpha,25-dihydroxyvitamin D3 receptor.

Authors:  R Ray; N Swamy; P N MacDonald; S Ray; M R Haussler; M F Holick
Journal:  J Biol Chem       Date:  1996-01-26       Impact factor: 5.157

6.  1alpha,25-Dihydroxyvitamin D3-3beta-(2)-bromoacetate, an affinity labeling derivative of 1alpha,25-dihydroxyvitamin D3 displays strong antiproliferative and cytotoxic behavior in prostate cancer cells.

Authors:  Narasimha Swamy; Kelly S Persons; Tai C Chen; Rahul Ray
Journal:  J Cell Biochem       Date:  2003-08-01       Impact factor: 4.429

7.  Affinity labeling of rat cytochrome P450C24 (CYP24) and identification of Ser57 as an active site residue.

Authors:  J L Omdahl; N Swamy; R Serda; A Annalora; M Berne; R Rayb
Journal:  J Steroid Biochem Mol Biol       Date:  2004-05       Impact factor: 4.292

8.  Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3.

Authors:  E Abe; C Miyaura; H Sakagami; M Takeda; K Konno; T Yamazaki; S Yoshiki; T Suda
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

9.  A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer.

Authors:  T R J Evans; K W Colston; F J Lofts; D Cunningham; D A Anthoney; H Gogas; J S de Bono; K J Hamberg; T Skov; J L Mansi
Journal:  Br J Cancer       Date:  2002-03-04       Impact factor: 7.640

10.  A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma.

Authors:  K Dalhoff; J Dancey; L Astrup; T Skovsgaard; K J Hamberg; F J Lofts; O Rosmorduc; S Erlinger; J Bach Hansen; W P Steward; T Skov; F Burcharth; T R J Evans
Journal:  Br J Cancer       Date:  2003-07-21       Impact factor: 7.640
View more
  3 in total

1.  PRL-3 engages the focal adhesion pathway in triple-negative breast cancer cells to alter actin structure and substrate adhesion properties critical for cell migration and invasion.

Authors:  Hamid H Gari; Gregory D DeGala; Rahul Ray; M Scott Lucia; James R Lambert
Journal:  Cancer Lett       Date:  2016-07-21       Impact factor: 8.679

2.  Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers.

Authors:  Hamid H Gari; Christy M Gearheart; Susan Fosmire; Gregory D DeGala; Zeying Fan; Kathleen C Torkko; Susan M Edgerton; M Scott Lucia; Rahul Ray; Ann D Thor; Christopher C Porter; James R Lambert
Journal:  Oncotarget       Date:  2016-03-29

3.  Loss of the oncogenic phosphatase PRL-3 promotes a TNF-R1 feedback loop that mediates triple-negative breast cancer growth.

Authors:  H H Gari; G D DeGala; M S Lucia; J R Lambert
Journal:  Oncogenesis       Date:  2016-08-15       Impact factor: 7.485
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.